Literature DB >> 21099107

Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Mark R Schleiss1.   

Abstract

The magnitude and durability of immunity to human cytomegalovirus (HCMV) following natural infection is compromised by the presence of immune modulation genes that appear to promote evasion of host clearance mechanisms. Since immunity to HCMV offers limited protection, rational design of effective vaccines has been challenging. In this issue of the JCI, Slavuljica and colleagues employ techniques to genetically modify the highly related mouse CMV (MCMV), in the process generating a virus that was rapidly cleared by NK cells. The virus functioned as a safe and highly effective vaccine. Demonstration of the ability to engineer a safe and highly effective live virus vaccine in a relevant rodent model of CMV infection may open the door to clinical trials of safer and more immunogenic HCMV vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099107      PMCID: PMC2993604          DOI: 10.1172/JCI45250

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.

Authors:  N Jan Chalupny; Annie Rein-Weston; Stephanie Dosch; David Cosman
Journal:  Biochem Biophys Res Commun       Date:  2006-05-24       Impact factor: 3.575

2.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.

Authors:  S B Boppana; L B Rivera; K B Fowler; M Mach; W J Britt
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

5.  The Natural Selection of Herpesviruses and Virus-Specific NK Cell Receptors.

Authors:  Joseph C Sun; Lewis L Lanier
Journal:  Viruses       Date:  2009       Impact factor: 5.048

6.  Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.

Authors:  Luka Cicin-Sain; Ivan Bubić; Margit Schnee; Zsolt Ruzsics; Christian Mohr; Stipan Jonjić; Ulrich H Koszinowski
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 7.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

8.  Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population.

Authors:  Aparecida Yulie Yamamoto; Marisa Marcia Mussi-Pinhata; Suresh B Boppana; Zdenek Novak; Virginia M Wagatsuma; Patricia de Frizzo Oliveira; Geraldo Duarte; William J Britt
Journal:  Am J Obstet Gynecol       Date:  2010-01-13       Impact factor: 8.661

Review 9.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

Review 10.  Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

Authors:  C Söderberg-Nauclér
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

View more
  1 in total

1.  Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?

Authors:  Mark R Schleiss
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.